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Abstract
Chamilová M.,  P.  Kubatka,  K.  Kal ická,  E.  Adámeková,  B.  Bojková,  I .  Ahlers ,
E.  Ahlersová:  Chemoprevention of N-methyl-N-nitrosourea Induced Mammary Carcino-
genesis with Raloxifene and Melatonin: Metabolic Changes in Female Rats. Acta Vet. Brno 2002,
71: 235–242.
The aim of this work was to determine the selected parameters of carbohydrate and lipid
metabolism in the mammary carcinogenesis induced with N-methyl-N-nitrosourea (NMU) in two
doses, each by 50 mg/kg of body weight with a 7-day interval between them within the postnatal
days 43 and 54 in female Sprague-Dawley rats. Chemoprevention started with the administration
of melatonin (MEL, 4 µg/ml in water, from 15.00 h to 08.00 h) 12 days and raloxifene (RAL
5 mg/kg, 2 × weekly) 10 days before the application of NMU. Twenty-four weeks following the
NMU administration the animals were killed, and the incidence, latency, frequency and volume of
tumours were evaluated. The animals were divided into: tumour-bearing (TB) and non-tumour-
bearing (NTB) with the influence of RAL, MEL and their combination. While RAL and RAL plus
MEL significantly decreased the incidence and frequency of tumours, the effect of isolated MEL
was substantially lower. In the serum, an increase in the concentration of serum glucose in TB and
also NTB animals was observed. In the liver of both the TB and NTB animals, the content of
cholesterol (CH) and triacylglycerols (TG) decreased and the contents of phospholipids (PL)
increased. RAL decreased the contents of CH and PL in the liver of NTB animals and increased
the concentration of TG in both groups of animals. Administration of RAL to NTB animals
decreased the concentrations of malondialdehyde (MDA) in the serum and thymus, in the bone
marrow also in TB animals. MEL decreased the concentration of MDA in the bone marrow of TB
animals. MEL increased the concentrations of serum glucose and glycogen content in the heart
muscle of NTB animals. RAL plus MEL decreased the concentration of serum TG and PL and
decreased the contents of CH and PL in the liver of TB as well as NTB animals. In the thymus and
liver, combination of RAL+MEL decreased the MDA content compared with the RAL alone in
NTB animals.
The co-effect of two or more substances will be probably the optimal way in prevention of
cancer. The co-effect of RAL and MEL shows to be a prospective way for influencing the
mammary tumors.
Breast cancer, female rats, raloxifene, melatonin, chemoprevention
The hormonal therapy of the breast carcinoma is an inseparable part of the variety of
therapeutic procedures. The substitution with estrogens has been considered for a long time
as a dominant indication of therapy in postmenopausal women, and it has been recognized
that approximately one third of women will have a benefit of this procedure. The use of
estrogens protects these women against osteoporosis and decreases the cardiovascular risk,
but on the other hand, increases the risk of breast and endometrium carcinoma (Col et al.
1997). With regard to the unfavourable effects of estrogens on the breast and endometrium
tissue, it was necessary to develop substances which could have a favourable estrogenic
effects on the bone tissue and cardiovascular system without increasing the risk of breast and
endometrium carcinoma. Raloxifene (RAL) represents the second generation of the
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substances called selective modulators of estrogen receptors (SERM). RAL is a non-steroid
antiestrogen with the structure of benzothiophene originally developed for the treatment and
prevention of osteoporosis in postmenopausal women. Preliminary results in women treated
for osteoporosis indicate that RAL reduces the risk of the incidence of breast carcinoma
without an unfavourable effect on the endometrium (Blum and Cannon 1998). Both
clinical and experimental studies have revealed the ability of RAL to decrease the total and
LDL cholesterol in the serum. The use of RAL in hormonal therapy in women is dependent
on the results of the presently running clinical studies (MORE, STAR).
The other efficient substance in the treatment of breast carcinoma is melatonin, the
principal hormonal product of the pineal gland. The function of this indolamine is closely
connected with the neuroendocrine, biorhythmical and immune functions (Guerrero and
Reiter  1992). Numerous authors have confirmed the oncostatic effects of melatonin in the
treatment of breast carcinoma (Lissoni  et al. 1989) and other types of carcinoma (Blask
1993).
The aim of our work was to find the effects of raloxifene, melatonin and their combination
on the selected metabolic parameters in N-methyl-N-nitrosourea induced mammary
carcinoma in female Sprague-Dawley rats and to compare their effects with the metabolic
effects of “classical” antiestrogen tamoxifen alone or in combination with melatonin
(Chamilová et al. 2001).
Materials and Methods
Female Sprague-Dawley rats (Anlab, Prague, Czech Republic) were used in the experiment. The animals were
delivered at the age of 34-38 days, and during the whole experiment they were kept under standard conditions
(23 ± 2 °C, relative air humidity 60-70 %, light regimen L:D 12:12 with the beginning of the light part of the day
at 07.00 h). During the experiment the animals (4-5 in a cage) were fed the PM diet (Top-Dovo, Dobrá Voda,
Slovak Republic) and drank tap water ad libitum. Chemocarcinogen N-methyl-N-nitrosourea (NMU; Sigma,
Deisenhofen, Germany) was administered to animals between the postnatal days 43 and 54 in two doses
intraperitoneally, each at 50mg/kg of body weight within 7 days. Chemoprevention with raloxifene (RAL) and
melatonin (MEL) started 10 days and 12 days before the administration of NMU, respectively, and lasted until
the end of the experiment. RAL (LY 139481-HCl, Eli Lilly and Co., Indianapolis, USA) was administered twice
a week subcutaneously in the dorsal region at a dose of 5 mg/kg of body weight of animals as 0.25 ml solution
of the mixture of PEG 400: water = 1:1. The animals drank MEL (Biosynth, Staad, Switzerland) in tap water at
a concentration of 4 µg/ml daily from 15.00 h to 08.00 h next day. For the preparation of 1 l solution 4 mg of
MEL was dissolved in 0.3 ml of ethanol and supplemented with tap water to the volume of 1 l. During the
experiment, the animals were weighed and palpated once a week, and their food and water intake was measured.
At the end of the experiment in week 24, the animals were killed by a quick decapitation and subsequently the
incidence and growth of mammary tumours and selected parameters of the lipid and carbohydrate metabolism
were analysed. In the serum of the mixed blood, following parameters were determined: the concentration of
triacylglycerols (TG), cholesterol (CH), phospholipids (PL) malondialdehyde (MDA) (as a measure of lipid
peroxidation) and glucose; in the liver, the contents of TG, PL, CH, MDA and glycogen; in the bone marrow the
concentrations of TG, PL, MDA; in the thymus only the content of MDA; in the heart muscle the glycogen
content. The concentration of phospholipids was determined from the lipid phosphorus by Bar t le t t ’ s  method
(1959), total cholesterol according to Zla tk is  et al. (1953), glycogen by the method of Roe  and Dai ley
(1966), malondialdehyde in a reaction with thiobarbituric acid (Satch  1978), triacylglycerols and glucose by
the commercial sets (Lachema).
At the evaluation 9 groups were compared:
1. NMU – non-tumour-bearing animals (NTB, n = 4)
2. NMU – tumour-bearing animals (TB, n = 4) 
3. NMU + RAL – non-tumour-bearing animals (NTB+RAL, n = 14) 
4. NMU + RAL – tumour-bearing animals (TB+RAL, n = 3) 
5. NMU + MEL – non-tumour-bearing animals (NTB+MEL, n = 6) 
6. NMU + MEL – tumour-bearing animals (TB+MEL, n = 8) 
7. NMU + RAL + MEL – non-tumour-bearing animals (NTB+RAL+MEL, n = 11) 
8. NMU + RAL + MEL – tumour-bearing animals (TB+RAL+MEL, n = 4)
9. Intact animals (INT, n = 10)
Results were statistically evaluated by the one-way analysis of variance for p < 0.05.
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Results
In the groups with RAL and RAL+MEL, the incidence decreased by 67 % and 65.5 %,
respectively. In the groups with RAL, RAL+MEL and MEL, the frequency per group
decreased by 90 %, 85 %, and by 50 %, respectively. Application of RAL lengthened the
latency by 27 days in both groups. In the groups with RAL and RAL+MEL, the tumour
volume was reduced, contrary to that in the group with MEL was increased. The weight gain
and relative weight of the uterus decreased in RAL and RAL+MEL groups in comparison
with those without RAL. In the food intake per animal and day there were no significant
differences in comparison with the control group. A decrease in the food intake per animal
and day was significant in the groups with RAL (RAL and RAL+MEL) in comparison with
those without RAL (group with MEL and control group). A decrease in the water intake per
animal and day was observed in the groups with RAL and RAL+MEL as compared with the
control group (Kubatka et al. in press). 
Serum
Glucose – an increase in the concentration of serum glucose was observed in both the
TB and NTB animals. In NTB and TB animals, MEL increased its concentration, in NTB
significantly.
Triacylglycerols  – in TB animals MEL and also RAL increased the concentration of
TG in the serum. Combination of RAL+MEL decreased the serum TG which were increased
by RAL. In NTB animals RAL and also RAL+MEL increased the TG concentration.
Phosphol ipids  – MEL and also RAL+MEL decreased the concentration of PL in the
serum of TB animals. RAL alone and also in combination with MEL decreased the PL
concentration, RAL+MEL decreased it also in comparison with MEL alone. 
Cholesterol  – no changes were observed.
Malondialdehyde – RAL decreased the concentration of MDA compared to its
combination with MEL in TB animals. In NTB animals, combination of RAL+MEL
increased the level of serum MDA that was decreased by RAL also in comparison with MEL
alone. 
Liver
Glycogen – combination of RAL+MEL increased the content of hepatic glycogen, also
when compared to RAL and MEL alone.
Triacylglycerols  – in both the TB and NTB animals there was a decrease in the content
of TG. In TB animals combination of RAL+MEL decreased the content of MEL-increased
TG.
Phosphol ipids  – the PL content was increased in both the TB and NTB animals. IN
TB animals RAL+MEL decreased the PL content also with regard to MEL alone. In NTB
animals RAL decreased the PL content, in combination with MEL decreased it only as
compared to MEL alone.
Cholesterol  – in both the TB and NTB animals, the CH content was decreased. In TB
animals RAL+MEL decreased the content of hepatic CH as compared to MEL. In NTB
animals RAL alone and also in combination with MEL decreased the CH content.
Malondialdehyde – an increase in the MDA content was observed in both groups of
animals. RAL+MEL decreased it as compared to RAL and MEL alone.
Thymus
Malondialdehyde – RAL+MEL decreased the content of MDA in NTB animals in




Metabolic effect of raloxifene and melatonin in the prevention of breast cancer in female Sprague-Dawley rats
NTB+R+MINT
4.64 ± 0.27
0.55 ± 0.09 0.42 ± 0.05 1.77 ± 0.32b 0.71 ± 0.11c 0.71 ± 0.13de 0,39 ± 0.12 1.23 ± 0.05h 0.63 ± 0.08 0.75 ± 0.06jk
2.28 ± 0.17 2.12 ± 0.15 1.78 ± 0.08 1.66 ± 0.13 c 1.53 ± 0.09 d 2.14 ± 0.030 1.57 ± 0.09 h 1.86 ± 0.11 1.53 ± 0.05jl
1.54 ± 0.09 1.36 ± 0.08 1.27 ± 0.09 1.25 ± 0.04 1.05 ± 0.13 1.27 ± 0.18 1.18 ± 0.05 1.21 ± 0.12 1.09 ± 0.05
4.92 ± 0.23 5.31 ± 0.31 4.51 ± 0.15 5.58 ± 0.22 5.62 ± 0.26 e 5.63 ± 0.36 4.33 ± 0.20 h 4.99 ± 0.35 6.10 ± 0.24kl
39.08 ± 8.65 31.29 ± 1.81 38.862 ± 3.09 32.82 ± 2.26 34.16 ± 6.20 25.54 ± 3.06 22.85 ± 2.24 33.62 ± 3.98 48.04 ± 4.7jkl
338.72 ± 5.1 95.61 ± 1.2a 162.09 ± 6.5 180.92 ± 1.2c 82.91 ± 3.1f 110.11 ± 6.2g 87.2 ± 9.6 185.44 ± 6.7 104.31 ± 4.8
260.81 ± 0.9 347.71 ± 6.1 a 322.87 ± 6.8 324.11 ± 4.2 238.41 ± 0.6df 300.31 ± 0.5g 254.9 ± 8.1h 319.71 ± 9.0 257.51 ± 2.2l
176.5 ± 6.3 133.0 ± 4.9 a 110.22 ± 6.7 125.3 ± 6.5 92.6 ± 3.4df 118.8 ± 4.4g 95.3 ± 3.8h 127.3 ± 8.0 97.6 ± 4.5jl
148.40 ± 8.61 202.41 ± 4.6a 264.76 ± 2.8 169.31 ± 2.1 157.22 ± 8.9 218.43 ± 8.2g 210.22 ± 0.4 164.0 ± 12.9 136.2 ± 4.3jkl
3.15 ± 0.43 3.87 ± 0.45 3.93 ± 0.79 3.34 ± 0.55 2.96 ± 0.33 2.69 ± 0.24 3.57 ± 0.29 2.51 ± 0.21 2.41 ± 0.19k
75.221 ± 0.29 35.581 ± 0.5a 157.51 ± 1.2b 46.752 ± 0.32 57.521 ± 2.3 e 99.184 ± 3.71 63.371 ± 4.50 78.082 ± 6.13 89.601 ± 7.70
17.94 ± 0.63 16.52 ± 1.14 16.16 ± 1.58 22.83 ± 4.43 15.86 ± 2.86 18.32 ± 3.19 19.96 ± 1.65 25.57 ± 6.16 18.84 ± 2.56
52.70 ± 5.52 77.03 ± 9.22a 11.33 ± 1.12b 45.36 ± 8.66c 145.91 ± 2.8def 85.933 ± 6.04 38.66 ± 7.15h 41.281 ± 3.76 196.11 ±18.64 jkl
5.30 ± 0.84 3.88 ± 0.38 8.54 ± 2.42 b 4.63 ± 0.38 3.13 ± 0.66 e 3.00 ± 0.37 4.32 ± 0.31 6.13 ± 0.61i 4.08 ± 0.21jl


































TB TB+R TB+M TB+R+M NTB NTB+R NTB+M
Data given as mean ± S.E.M., significance of differences on the level p < 0.05 depicted as symbol (a-l) used.
a – TB vs INT
b – TB+RAL vs TB
c – TB+MEL vs TB 
d – TB+RAL+MEL vs TB 
e – TB+RAL+MEL vs TB+RAL
f – TB+RAL+MEL vs TB+MEL
g – NTB vs INT
h – NTB+RAL vs NTB
i – NTB+MEL vs NTB
j – NTB+RAL+MEL vs NTB
k – NTB+RAL+MEL vs NTB+RAL
L – NTB+RAL+MEL VS NTB+MEL
INT – intact animals, TB – (NMU)-treated tumour-bearing, TB+RAL – (NMU)-treated tumour-bearing with raloxifene,
TB+MEL – (NMU)-treated tumour-bearing with melatonin, TB+RAL+MEL – (NMU)-treated tumour-bearing rats with
raloxifene and melatonin, NTB – (NMU)-treated non-tumour-bearing, NTB+RAL – (NMU)-treated non-tumour-bearing with
raloxifene, NTB+MEL – (NMU)-treated non-tumour-bearing with melatonin, NTB+RAL+MEL – (NMU)-treated non-tumour-
bearing rats with raloxifene and melatonin; GLU – glucose, GLY – glycogen, CH – cholesterol, TG – triacylglycerols, PL –
phospholipids, MDA – malondialdehyde
Bone marrow
Triacylglycerols  – in TB animals a decrease in TG concentration was observed in
bone marrow. RAL+MEL decreased the concentration of RAL-increased TG. 
Phosphol ipids  – no changes was observed.
Malondialdehyde – in TB animals the concentration of MDA was increased. MEL
and RAL alone decreased the MDA concentration, however, their combination increased it
in TB animals. In NTB animals, combination of RAL+MEL also increased the concentration
of MDA, which was decreased by RAL and MEL. 
Heart muscle
Glycogen – in TB animals RAL+MEL decreased the content of glycogen, which was
increased by RAL. In NTB animals the glycogen content was increased by MEL, in
combination with RAL it was decreased. RAL+MEL increased the content of myocardial
glycogen. The data are summarized in Table 1.
Discussion
The experimental carcinogenesis of mammary gland induced by chemocarcinogens
DMBA or NMU is mostly dependent on the hormonal state of the host (Welsch 1985).
The mammary tumours induced by NMU were confirmed to be more sensitive to estrogens
and growth hormones and less sensitive to prolactin in comparison with those induced by
DMBA (El-Bayoumy 1994). Hormone-dependent tumours appear to be a suitable
experimental model for classification and testing the chemopreventive substances with their
potential using in clinical practice. Testing the effect of individual substances with
assumption of there including in human pathology, besides the effect on the tumour growth
the knowledge of influencing the metabolism of the host organism is important.
The cancer disease, like the carcinogen itself, influences the metabolic patterns in the host
metabolism. There are precise data analyzing the lipid metabolism in experimental and
human oncology. A direct relationship between breast carcinoma and cholesterol
metabolism has not been confirmed yet. However, this is not the case in the carcinoma of
the colon and lung and in haematological neoplasia, where decrease in its serum
concentration has been confirmed by several authors (Dessi  et al. 1992; Rose et al. 1974;
Spiegel  et al. 1982). In our experiment, no changes in the serum lipids in the carcinogen
(NMU)-influenced animals were observed. In the liver of the both TB and NTB animals, a
decrease in CH and TG and increase in PL were observed. Within the process of
tumorigenesis the content of phosphocholine fraction of PL: phosphatidylcholine and
phosphatidylethanolamine increases in the epithelial cells of the mammary gland
(Aboagye and Bhujwalla  1999). In this connection, it is important to accent the finding
of increased content of PL in the liver of TB and NTB animals in our experiment. In the liver
of TB and NTB animals, an increased content of MDA was observed, which confirms the
increase in peroxidation of lipids by the influence of the carcinogen as well as the cancer
itself. The carbohydrate metabolism of the organism with tumour is characterized, above all,
by the increased glucogenesis. In TB and NTB animals an increased concentration of serum
glucose was observed.
Raloxifene belongs to the selective modulators of estrogen receptors and displays
estrogen-agonistic effect to bones and lipid metabolism and estrogen-antagonistic effect on
the uterine mucosa and breast tissue (Scot t  et al. 1999). Previous studies showed that RAL
reduces the risk of breast carcinoma in women treated for osteoporosis without an
unfavourable effect on the endometrium (Blum and Cannon 1998). RAL decreased LDL
cholesterol, but did not influence the concentration of HDL cholesterol and triacylglycerols
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in the serum of patients with breast carcinoma (Delmas et al. 1997). Decrease in insulin
growth factor-1 and in serum insulin/glucose ratio was noted in nondiabetic postmenopausal
women, treated for osteoporosis by raloxifene (Oleksik et al. 2001). Serum non-HDL
cholesterol and the index apolipoprotein-B/apolipoprotein-A1 were lowered in healthy
postmenopausal women, receiving daily 60mg of raloxifene; the same effect was gained by
hormone replacement therapy (Anderson et al. 2001). We confirm that RAL reduced the
content of CH and PL in the liver in NTB animals; in the serum its effect on CH was not
observed. In contrary, RAL increased the TG concentrations in both groups. Due to the
effect of RAL, there was a decrease in the concentration of MDA in the serum and thymus
(in combination of RAL+MEL) in NTB animals and in the bone marrow in both groups of
animals. 
In many experiments MEL showed the ability to inhibit the breast tissue of spontaneous
but mainly in chemically induced tumours. A full oncostatic effect has been proved under
the in vitro conditions in the cells of mammary and prostatic carcinomas, whose growth is
hormone-dependent (review: Cos and Sánchez-Barceló 2000). Cos et al. (1996) have
confirmed a direct inhibitory effect of MEL on the proliferation of human MCF-7 breast
carcinoma cells, RL95-2 of endometrium carcinoma and SK-N-SH of neuroblastoma cell
lines. MEL significantly lengthens duration of the cell cycle of human breast carcinoma
cells. MEL added into the cultivation medium together with [3H] thymidine shifts the period
of the MCF-7 cell cycle from 20.36 to 23.48 h. There are few data about the effect of MEL
on the host metabolism. A decrease in the serum CH and inhibition of lipogenesis in the
adipocytes of healthy rats were described by Vaughan and Vaughan (1993). In TB
animals, the application of MEL increased the concentration of TG and decreased the
concentration of PL in the serum and decreased the concentration of MDA in the bone
marrow. MEL significantly influences also the carbohydrate metabolism. Several authors
have demonstrated that MEL can suppress the release of insulin, while pinealectomy
decreases the concentration of serum glucose (Quay and Gorray 1980). Bai ley et al.
(1974) confirmed the inhibition of glucose-induced secretion of insulin by MEL. Depressive
effect of intracerebrally administered MEL on hyperglycaemia induced by 2-deoxyglucose
has been proved (Shima et al. 1997). MEL increased the concentration of serum glucose
and content of glycogen in the myocardium of NTB animals in our experiment; this should
be connected with a reduced effect of insulin on the periphery.
With regard to the efficacy of two chemoprotective substances used, the combination was
more expressive than their individual application. Their combination decreased the RAL-
increased concentration of serum TG and decreased the concentration of PL in the serum of
both groups of animals. A decrease in the content of CH and PL in the liver was observed in
TB as well in NTB animals; in the liver of TB animals due to combination a decrease in MEL-
increased content of TG occurred. Different results were observed in the concentration /content
of MDA. In the serum, RAL+MEL increased the concentration of MDA as compared to RAL
alone; in the bone marrow increased it in both groups of animals. In the thymus and liver, the
combination decreased the MDA content as compared to RAL alone in NTB animals.
More studies have confirmed that tamoxifen, unlike raloxifene, increases the
concentration of serum TG in breast carcinomas (Kanel  et al. 1997). In our experiment,
the rise of serum TG under the influence of RAL was noted in TB and NTB rats, but a
decrease occurred after combined RAL+MEL treatment. Hozumi et al. (2000) compared
the effect of RAL and TAM in the lipid metabolism under the in vitro conditions. They
concluded that RAL and TAM significantly reduced the intracellular concentration of CH
in HepG2 cells and TAM can increase the serum TG and so can participate in fatty liver
induction in sensitive patients. These authors consider RAL a safer component in the therapy
of the patients with unstable level of TG or with predisposition to hypertriacylglycerolemia.
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In DMBA-induced mammary carcinogenesis, an increase in the concentration of TG in the
serum was observed after application of tamoxifen; contrariwise after induction with NMU
a decrease of TG was recorded (Chamilová et al. 2001). In this experiment RAL, at
variance with described results, increased the concentration of TG in the serum. In both
experiments with TAM, its effect manifested in a decrease in the concentration of serum CH,
in NMU also in a reduction of CH content in the liver. RAL did not have an effect on the
serum CH, however, reduced its content in the liver. 
The effort to find the most suitable drug for cancer prevention has led us to select and
combine substances that are more efficient so that the best results would be achieved.
Co-effect of two or more substances will be probably the optimal way in the therapy but also
in prevention of cancer. The co-effect of RAL and MEL show to be a prospective method in
experimental breast cancer prevention.
Chemoprevencia raloxifénom a melatonínom u N-metyl-N-nitrózoureou
indukovanej mamárnej karcinogenézy: metabolické zmeny u samíc potkanov
Cieºom práce bolo stanoviÈ vybrané ukazovatele sacharidového a lipidového
metabolizmu u mamárnej karcinogenézy indukovanej N-metyl-N-nitrózoureou (NMU) v
dvoch dávkach, kaÏdá po 50mg/kg hmotnosti medzi 43.-54. postnatálnym dÀom u samíc
potkanov Sprague-Dawley. Chemoprevencia zaãala aplikáciou melatonínu (MEL, 4 µg/ml
vo vode, cirkadiánne) 12 dní a raloxifénu (RAL, 5 mg/kg 2x t˘Ïdenne) 10 dní pred
aplikáciou NMU. Po 24 t˘ÏdÀoch od podania NMU boli zvieratá usmrtené, bola hodnotená
incidencia, latencia, frekvencia a objem nádorov. Zvieratá sme rozdelili do dvoch veºk˘ch
ãastí: nádorové (TB) a nenádorové (NTB), s ovplyvnením RAL, MEL a ich kombináciou.
Zatiaº ão RAL a RAL plus MEL v˘znamne zníÏili incidenciu a frekvenciu nádorov, úãinok
izolovaného MEL bol podstatne men‰í. V sére sme pozorovali zv˘‰enie koncentrácie
sérovej glukózy u TB aj NTB zvierat. V peãeni TB aj NTB zvierat sa zníÏil obsah
cholesterolu (CH) a triacylglycerolov (TG) a zv˘‰il obsah fosfolipidov (PL). RAL zníÏil
obsah CH a PL v peãeni NTB zvierat, zv˘‰il koncentráciu TG u TB aj NTB zvierat.
Podanie RAL u NTB zvierat zníÏilo koncentráciu malonyldialdehydu (MDA) v sére a
t˘muse, v kostnej dreni aj u TB zvierat. MEL zníÏil koncentráciu MDA v kostnej dreni TB
zvierat. MEL zv˘‰il koncentráciu sérovej glukózy a obsah glykogénu v myokarde NTB
zvierat. RAL+MEL zníÏili koncentráciu sérov˘ch TG a PL a zníÏili obsah CH a PL v
peãeni TB aj NTB zvierat. V t˘muse a peãeni kombinácia látok zníÏila obsah MDA oproti
samotnému RAL u NTB zvierat.
Spolupôsobenie dvoch, resp. viacer˘ch substancií bude pravdepodobne optimálnou
cestou v prevencii nádorov˘ch ochorení. Spoloãné pôsobenie RAL a MEL sa ukazuje ako
perspektívny spôsob ovplyvnenia nádorového ochorenia mlieãnej Ïºazy.  
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